Bioasis Technologies Inc. (OTCMKTS:BIOAF – Get Rating) saw a large increase in short interest during the month of December. As of December 30th, there was short interest totalling 73,600 shares, an increase of 429.5% from the December 15th total of 13,900 shares. Based on an average daily volume of 124,100 shares, the short-interest ratio is presently 0.6 days.
Bioasis Technologies Price Performance
Shares of BIOAF stock opened at $0.04 on Wednesday. The company has a 50 day moving average of $0.08 and a 200-day moving average of $0.11. Bioasis Technologies has a 12-month low of $0.02 and a 12-month high of $0.25. The firm has a market cap of $2.90 million, a P/E ratio of -0.91 and a beta of 0.40.
Get
Bioasis Technologies alerts:
Bioasis Technologies (OTCMKTS:BIOAF – Get Rating) last issued its quarterly earnings results on Friday, October 28th. The company reported ($0.01) earnings per share (EPS) for the quarter. The firm had revenue of $0.09 million for the quarter. As a group, equities analysts expect that Bioasis Technologies will post -0.03 EPS for the current year.
About Bioasis Technologies
(Get Rating)
Bioasis Technologies Inc, a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases.
Featured Articles
- Get a free copy of the StockNews.com research report on Bioasis Technologies (BIOAF)
- Does it Matter Folks Aren't "Starry-Eyed" Over Pepsi's New Soda?
- Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?
- Can Alaska Air Continue Soaring Above The Airline Industry?
- Insulet Has Potential To Gain More Than Analysts Are Forecasting
- Cathie Wood Is Buying These Stocks, Should You?
Receive News & Ratings for Bioasis Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioasis Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
生物绿洲科技公司(BiOASIS Technologies Inc.)在12月份见证了空头股数的大幅增长。截至12月30日，空头股数共有73,600股，比12月15日的13,900股增加了429.5%。以日均成交量12.41万股计算，目前短息比率为0.6天。
BiOASIS技术性价比
周三，BIOAF的股票开盘报0.04美元。该公司的50日移动均线切入位在0.08美元，200日移动均线切入位在0.11美元。BiOasis Technologies的12个月低点为0.02美元，12个月高位为0.25美元。该公司的市值为290万美元，市盈率为-0.91，贝塔系数为0.40。
到达
BiOASIS技术警报：
BiOasis Technologies(OTCMKTS：BIOAF-GET Rating)上一次发布季度收益报告是在10月28日(星期五)。该公司公布了该季度每股收益(EPS)(0.01美元)。该公司本季度的收入为90万美元。作为一个整体，股票分析师预计BiOASIS Technologies本年度的每股收益将达到0.03欧元。
关于BiOASIS技术公司
(获取评级)
BiOASIS技术公司是一家处于发展阶段的生物制药公司，致力于神经疾病和障碍的诊断和治疗产品的研究和开发。它正在开发xB3，这是一种通过血脑屏障(BBB)运输治疗剂的平台技术；以及治疗中枢神经系统疾病(CNS)，包括脑癌，以及代谢和神经退行性疾病。
专题文章
- 免费获取StockNews.com关于BiOASIS技术的研究报告(BIOAF)
- 人们对百事可乐的新苏打水不感兴趣，这有什么关系吗？
- 强生的突破：盈利能提振股市吗？
- 阿拉斯加航空能否继续在航空业之上高歌猛进？
- Insulet有潜力获得超过分析师预测的收益
- 凯西·伍德正在购买这些股票，你应该这样做吗？
接受《BiOASIS技术日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯，接收最新新闻和分析师对BiOasis Technologies及相关公司的评级的每日摘要。
